DE60017287D1 - SPECIFIC ANONISTS FOR PERIPHERAL CANNABINOID RECEPTORS - Google Patents

SPECIFIC ANONISTS FOR PERIPHERAL CANNABINOID RECEPTORS

Info

Publication number
DE60017287D1
DE60017287D1 DE60017287T DE60017287T DE60017287D1 DE 60017287 D1 DE60017287 D1 DE 60017287D1 DE 60017287 T DE60017287 T DE 60017287T DE 60017287 T DE60017287 T DE 60017287T DE 60017287 D1 DE60017287 D1 DE 60017287D1
Authority
DE
Germany
Prior art keywords
specific
compounds
activity
cannabinoid receptors
peripheral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017287T
Other languages
German (de)
Other versions
DE60017287T2 (en
Inventor
Ester Fride
Aviva Breuer
Lumir Hanus
Susanna Tchilibon
Michal Horowitz
Raphael Mechoulam
Aaron Garzon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of DE60017287D1 publication Critical patent/DE60017287D1/en
Application granted granted Critical
Publication of DE60017287T2 publication Critical patent/DE60017287T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
DE60017287T 1999-10-31 2000-10-30 Specific agonists for peripheral cannabinoid receptors Expired - Lifetime DE60017287T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL132661A IL132661A (en) 1999-10-31 1999-10-31 Agonists specific for the peripheral cannabinoid receptor
IL13266199 1999-10-31
PCT/US2000/029903 WO2001032169A1 (en) 1999-10-31 2000-10-30 Agonists specific for the peripheral cannabinoid receptor

Publications (2)

Publication Number Publication Date
DE60017287D1 true DE60017287D1 (en) 2005-02-10
DE60017287T2 DE60017287T2 (en) 2005-12-08

Family

ID=11073405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017287T Expired - Lifetime DE60017287T2 (en) 1999-10-31 2000-10-30 Specific agonists for peripheral cannabinoid receptors

Country Status (13)

Country Link
US (3) US6864291B1 (en)
EP (1) EP1244440B1 (en)
JP (1) JP4231906B2 (en)
KR (1) KR100770695B1 (en)
AT (1) ATE286389T1 (en)
AU (1) AU778149B2 (en)
CA (1) CA2385928A1 (en)
DE (1) DE60017287T2 (en)
HU (1) HUP0203681A3 (en)
IL (2) IL132661A (en)
NZ (1) NZ518054A (en)
WO (1) WO2001032169A1 (en)
ZA (1) ZA200202181B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
ATE247097T1 (en) 1998-05-04 2003-08-15 Univ Connecticut ANALGESIC AND IMMUNOMODULATING CANNABINOIDS
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
AU778159B2 (en) 1999-10-18 2004-11-18 University Of Connecticut, The Peripheral cannabinoid receptor (CB2) selective ligands
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for the peripheral cannabinoid receptor
US7329651B2 (en) * 2001-01-26 2008-02-12 University Of Connecticut Cannabimimetic ligands
JP2005503998A (en) * 2001-01-29 2005-02-10 ユニバーシティ オブ コネチカット Receptor-selective cannabi mimetic aminoalkylindoles
JP4312594B2 (en) * 2001-07-13 2009-08-12 ユニバーシティ オブ コネチカット Novel bicyclic and tricyclic cannabinoids
US7666867B2 (en) 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
WO2003061699A1 (en) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedies for allergic diseases
EP1469842A4 (en) * 2002-01-31 2006-04-26 Pharmos Corp Bicyclic cb2 cannabinoid receptor ligands
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
CN1678303A (en) 2002-08-23 2005-10-05 康涅狄格大学 Keto cannabinoids with therapeutic indications
EP1606019A1 (en) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
AR043633A1 (en) * 2003-03-20 2005-08-03 Schering Corp CANABINOID RECEIVERS LINKS
ATE496901T1 (en) * 2003-05-20 2011-02-15 Univ Tennessee Res Foundation CANNABINOID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
CA2571679A1 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington's disease
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
CA2650566A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
WO2008001369A1 (en) * 2006-06-27 2008-01-03 Pharmos Corporation Use of cb2 receptor agonists for promoting neurogenesis
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
WO2009044402A1 (en) 2007-10-02 2009-04-09 Ariel - University Research And Development Company Ltd. Endocannabinoids for enhancing growth and development in infants
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010041253A1 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
EP2456428A1 (en) 2009-07-23 2012-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
ITMI20122221A1 (en) 2012-12-21 2014-06-22 C4T S C A R L NEW COMPOUNDS OF 2,3-DIIDRO-4H-1,3-BENZOSSAZIN-4-ONE, METHOD FOR PREPARING THEM AND PHARMACEUTICAL FORM THAT INCLUDES THEM
WO2014170902A1 (en) 2013-04-17 2014-10-23 Ariel - University Research And Development Company, Ltd. Cb2 receptor ligands for the treatment of psychiatric disorders
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2019030762A2 (en) 2017-08-09 2019-02-14 Stahl Veronica Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects
EP3836894A1 (en) * 2019-10-25 2021-06-23 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55274A (en) 1978-08-02 1982-08-31 Yissum Res Dev Co 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
FR2735774B1 (en) 1995-06-21 1997-09-12 Sanofi Sa USE OF HUMAN CB2 RECEPTOR AGONIST COMPOUNDS FOR THE PREPARATION OF IMMUNOMODULATORY DRUGS, NOVEL CB2 RECEPTOR AGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for the peripheral cannabinoid receptor

Also Published As

Publication number Publication date
CA2385928A1 (en) 2001-05-10
KR100770695B1 (en) 2007-10-29
DE60017287T2 (en) 2005-12-08
AU1245801A (en) 2001-05-14
NZ518054A (en) 2003-10-31
US20050165118A1 (en) 2005-07-28
JP2004505006A (en) 2004-02-19
US7214716B2 (en) 2007-05-08
US6864291B1 (en) 2005-03-08
AU778149B2 (en) 2004-11-18
IL148796A (en) 2008-11-26
WO2001032169A1 (en) 2001-05-10
IL132661A0 (en) 2001-03-19
IL132661A (en) 2008-11-26
EP1244440A1 (en) 2002-10-02
HUP0203681A2 (en) 2003-04-28
US20020173528A1 (en) 2002-11-21
EP1244440A4 (en) 2003-05-14
JP4231906B2 (en) 2009-03-04
ZA200202181B (en) 2003-05-28
HUP0203681A3 (en) 2003-05-28
KR20030008208A (en) 2003-01-24
US6903137B2 (en) 2005-06-07
ATE286389T1 (en) 2005-01-15
EP1244440B1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60017287D1 (en) SPECIFIC ANONISTS FOR PERIPHERAL CANNABINOID RECEPTORS
EA200101019A1 (en) GLUCOCORTICOID RECEPTOR MODULATORS
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0222495D0 (en) Compounds
PA8493701A1 (en) COMPOUNDS TO TREAT OBESITY
BR0208150A (en) Mch antagonists and their application in obesity treatment
BR0307429A (en) Compound, use thereof, pharmaceutical composition, and method for treating h3 histamine receptor related disorders or diseases
EA200700934A1 (en) PYRIMIDINE DERIVATIVES AND THEIR APPLICATION AS CB2 MODULATORS
MXPA05012011A (en) Therapeutic use of anti-cs1 antibodies.
ATE330967T1 (en) PEPTIDE COMPOUNDS BINDING TO HER2
BRPI0410721A (en) foamable pharmaceutical compositions and methods for treating a disorder
WO1999063930A3 (en) Novel angiotensin receptor modulators and their uses
EA200701036A1 (en) LACTAMIC COMPOUNDS AND THEIR APPLICATION AS PHARMACEUTICAL PREPARATIONS
WO2002030980A3 (en) Use of anti-human integrin alpha d antibodies to treat spinal cord injury
EA200500378A1 (en) NEW IMIDAZOL COMPOUNDS AS A TRANSFORMING GROWTH FACTOR INHIBITORS (TGF) INHIBITORS
DE60005485D1 (en) INDOLDER DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS
TW200611695A (en) Pyrrolopyridine derivatives
BR0307508A (en) Compound, pharmaceutical composition, and methods of treating or preventing pain and inflammation and treating disease
TR199900318T2 (en) IL-8 receptor antagonists.
ATE479655T1 (en) NEW AMINOAZETIDINE, AMINOPYRROLIDINE AND AMINOPIPERIDINE DERIVATIVES
SE9900961D0 (en) Novel compounds
WO2010042489A3 (en) Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
CR6824A (en) ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS
BR0012175A (en) Igiur5 receptor antagonists, selective for the treatment of migraine
DK1525215T3 (en) Modulators for the progesterone receptor with elevated anti-gonadotropic activity for women's fertility control and hormone replacement therapy

Legal Events

Date Code Title Description
8364 No opposition during term of opposition